Diarylquinolines (DARQs) are a chemical class of drugs that treattuberculosis. They target subunit c ofmycobacterialATP synthase,^[1] inhibiting the enzyme somycobacterium tuberculosis cannot synthesise ATP. This effectively kills the bacteria.

AlthoughATP synthase in bacteria is similar to its eukaryotic analogue, diarylquinoline agents (such as TMC207) are very specific to the bacterial enzyme,^[2] so were expected to be safe for use in humans and other eukaryotes. This also suggests that bacterial ATP synthase inhibition is an attractive therapeutic target.^[2]

bedaquiline (previously TMC207)

A 1,4-diarylquinoline (phenyl andnaphthyl).US FDA approval in 2012. As of 2014, the only licensed indication of the drug bedaquiline is in the treatment ofmulti-drug-resistant tuberculosis, primarily due to concerns about safety.^{[citation needed]}

The reaction ofarylaldehyde,malonodinitrile, and3‐arylamino‐5,5‐dimethylcyclohex‐2‐enone can produce 1,4-diarylquinolines.^[3]

The reaction ofenamides andimines can produceheteroaromatic quinoline derivatives.^[4]

• Anti-tuberculosis drugs
• Quinolines

• Articles with short description
• Short description is different from Wikidata
• All articles with unsourced statements
• Articles with unsourced statements from August 2022